Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jun Itakura
Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
Guarantor of this article: Masayuki Kurosaki. Shun Ishido and Nobuharu Tamaki contributed equally to this study. Key Clinical Message The liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.
Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C
Highlights • Multiple direct-acting antiviral regimen failures may generate multiple RASs. • Prevalence of RASs increased according to the number of failed regimens. • These mutations contribute to viral resistance to multiple treatment regimens. • These mutations must be considered in decision making of chronic hepatitis C treatment.
Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct acting antivirals - Tamaki - - Journal of Viral Hepatitis - Wiley Online Libr
Email or Customer ID Please check your email for instructions on resetting your password. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account.
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS3/4A inhibitor, asunaprevir (ASV), in patients with chronic hepatitis C virus genotype 1b infection. This is a nationwide multicenter study conducted by the Japanese Red Cross Liver Study Group. The sera were obtained from 68 patients with virological failure after 24 weeks of DCV/ASV treatment.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jun
Contact Jun, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack